Cannabis Extract Nearly Doubled the Rate of Muscle Stiffness Relief in Multiple Sclerosis | Research

The takeaway

In a large Phase III trial, oral cannabis extract was nearly twice as effective as placebo in relieving MS-related muscle stiffness, with additional benefits for pain, spasms, and sleep quality.

Read this if you have MS-related spasticity and want to see the clinical trial evidence for cannabis extract.

29.4% relief with cannabis extract vs. 15.7% with placebo (p=0.004)

What the researchers found

The MUSEC trial randomized 279 MS patients across 22 UK centers to oral cannabis extract or placebo. After 12 weeks, the rate of relief from muscle stiffness was nearly double in the cannabis extract group compared to placebo (29.4% vs. 15.7%). The treatment effect appeared by week 4 and was maintained through week 12.

Similar improvements were seen for body pain, muscle spasms, and sleep quality. Multiple MS-specific patient-reported outcome measures corroborated these findings. Adverse events were consistent with known cannabinoid side effects, and no new safety concerns emerged.

Why it matters

MS-related spasticity significantly impairs quality of life and is often inadequately managed with existing medications. This large, well-designed trial provided strong evidence that oral cannabis extract offers meaningful symptom relief beyond what patients experience with placebo.

The numbers in context

279 patients, 22 UK centers. Stiffness relief at 12 weeks: 29.4% CE vs. 15.7% placebo (OR 2.26; 95% CI 1.24-4.13; p=0.004). Dose range: 5-25 mg THC daily. Benefits also seen for pain, spasms, and sleep. Trial registration: NCT00552604.

How the study worked

Double-blind, placebo-controlled, Phase III RCT at 22 UK centers. 144 patients received cannabis extract, 135 received placebo. Two-week dose titration from 5 mg to maximum 25 mg THC daily, followed by 10-week maintenance. Primary outcome: category rating scale for patient-reported muscle stiffness change from baseline.

What this study cannot tell us

Patient-reported outcomes are subjective and may be influenced by expectations. Despite blinding, some patients may have recognized cannabinoid effects. The 12-week duration does not address long-term efficacy. The one-sided p-value threshold is less conservative than two-sided testing.

How to read the evidence

Large multi-center Phase III RCT with clear primary endpoint; strong evidence for efficacy.

When this study was published

Published in 2012. This trial was a key contributor to the evidence base for cannabinoid MS treatments.

The bigger picture

The MUSEC trial added to a growing body of Phase III evidence supporting cannabis-based treatments for MS spasticity. Together with earlier large trials (CAMS, CUPID), this study helped establish the evidence base that led to broader regulatory acceptance of cannabinoid medicines for MS.

Questions still open

Does the benefit persist beyond 12 weeks? Which patients are most likely to respond? How does oral cannabis extract compare head-to-head with Sativex for MS spasticity?

Common questions

How effective was the cannabis extract for MS stiffness?

After 12 weeks, 29.4% of patients on cannabis extract reported relief from muscle stiffness compared to 15.7% on placebo. Patients were roughly twice as likely to experience meaningful stiffness relief with the cannabis extract. Benefits were also seen for pain, spasms, and sleep quality.

What dose was used?

Patients started at 5 mg of THC daily and gradually increased over two weeks to a maximum of 25 mg daily, finding their optimal dose. They then maintained that dose for 10 weeks. This gradual titration approach minimizes side effects while finding the effective dose for each patient.

Read the original research

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

Journal of neurology, neurosurgery, and psychiatry, 83(11), 1125-32

View on PubMed ↗Publisher’s paper ↗

Citation

Zajicek, John Peter; Hobart, Jeremy C; Slade, Anita; Barnes, David; Mattison, Paul G. (2012). Multiple sclerosis and extract of cannabis: results of the MUSEC trial.. Journal of neurology, neurosurgery, and psychiatry, 83(11), 1125-32. https://doi.org/10.1136/jnnp-2012-302468